{"entity":{"id":"zai-lab","kind":"company","name":"Zai Lab","aka":["再鼎医药"],"tldr":"Zai Lab is the in-licensing pioneer that brings Western cancer drugs to China (niraparib, zanidatamab, repotrectinib, Tumour Treating Fields) and now exports its own bispecific and ADC assets.","summary":"Founded by Samantha Du; built on Greater China rights to niraparib (Zejula), zanidatamab, repotrectinib, tislelizumab-adjacent assets, sulbactam-durlobactam and Optune, with a Shanghai commercial organisation of hundreds. Internal pipeline: ZL-1310 (DLL3 ADC), ZL-1503 and the LRRC15 ADC ZL-6201 from MediLink. A bridge company: it explains how Western drugs reach Chinese patients years earlier than they otherwise would.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.zailaboratory.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy","adcs"],"technologies":[],"targets":[],"drugs":["niraparib","zanidatamab","repotrectinib","optune","zl-1310"],"companies":["gsk","jazz","zymeworks","novocure","medilink"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06885281"],"people":["du-samantha"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai / Cambridge, MA","country":"CN","companyType":"biotech","website":"https://www.zailaboratory.com/","ticker":"ZLAB / 9688.HK","founded":2014,"investors":[],"funding":[]},"route":"/companies/zai-lab/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/"},{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/"},{"id":"zl-1310","kind":"drug","name":"ZL-1310","route":"/drugs/zl-1310/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"},{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/"},{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"},{"id":"novocure","kind":"company","name":"Novocure","route":"/companies/novocure/"},{"id":"zymeworks","kind":"company","name":"Zymeworks","route":"/companies/zymeworks/"}],"trial":[{"id":"nct07796100","kind":"trial","name":"A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther","route":"/trials/nct07796100/"},{"id":"nct06885281","kind":"trial","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","route":"/trials/nct06885281/"},{"id":"dllevate","kind":"trial","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","route":"/trials/dllevate/"}],"person":[{"id":"du-samantha","kind":"person","name":"Samantha Du (Du Ying)","route":"/people/du-samantha/"}]}}